Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Nadroparin Calcium in Patients with Subarachnoid Hemorrhage

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called nadroparin calcium in patients who have experienced a subarachnoid hemorrhage, which is a type of bleeding in the brain. The study aims to determine if patients treated with a therapeutic dose of nadroparin calcium have a lower risk of death within 30 days compared to those receiving a lower, prophylactic dose. Nadroparin calcium is administered as a solution for injection under the skin.

Participants in the study will receive either a therapeutic or prophylactic dose of nadroparin calcium. The study will monitor various outcomes, including the rate of death within 30 days, as well as other potential complications such as delayed cerebral ischemia, which is a condition where the brain does not get enough blood, and venous thrombo-embolic complications, which involve blood clots. The study will also look at the occurrence of bleeding complications, the need for additional medical procedures, and the overall quality of life and cognitive functioning of the participants.

The study will continue for several months, with follow-up assessments to evaluate the participants' health and recovery. These assessments will include checking for any new or ongoing health issues, such as hydrocephalus, which is a condition where fluid builds up in the brain, and the participants' ability to return to their normal daily activities. The study will also use MRI scans to check for any changes in the brain, such as small areas of tissue damage, at six months after the initial treatment. The goal is to gather comprehensive data on the effectiveness and safety of nadroparin calcium in improving outcomes for patients with subarachnoid hemorrhage.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after confirmation of a subarachnoid hemorrhage (SAH) through a CT scan or lumbar puncture, with the causative aneurysm confirmed by CT-A and/or DSA.

    The aneurysm must be treated with coiling within 72 hours of the initial SAH.

    Informed consent is required before the first administration of the study medication.

    Participants must be adults, aged 18 years or older.

  2. Step 2

    Medication administration

    The study involves the administration of nadroparin calcium, a medication given as a solution for injection.

    The medication is administered subcutaneously, which means it is injected under the skin.

    Two dosages are used: 5,700 IU in 0.6 mL and 2,850 IU in 0.3 mL, provided in pre-filled syringes.

    The objective is to evaluate whether patients treated with a therapeutic dose of low molecular weight heparin (LMWH) have a lower 30-day mortality rate compared to those treated with a prophylactic dose.

  3. Step 3

    Monitoring and evaluation

    The primary endpoint is the mortality rate at 30 days.

    Secondary endpoints include delayed cerebral ischemia, venous thrombo-embolic complications, hemorrhagic complications, hydrocephalus, discharge location, quality of life, cognitive functioning, clinical outcome, rate of infarctions, and mortality at six months.

    Participants will undergo assessments to monitor these outcomes throughout the study duration.

  4. Step 4

    Study duration

    The estimated end date for the trial is December 31, 2026.

    The recruitment for the study began on February 1, 2022.

Who can join the trial?

6 criteria

  • The patient must have a **subarachnoid hemorrhage (SAH)**, which is bleeding in the space around the brain, confirmed by a **CT scan** (a type of detailed X-ray) or **lumbar puncture** (a procedure where fluid is taken from the spine).
  • The cause of the bleeding, an **aneurysm** (a bulge in a blood vessel), must be confirmed by **CT-A** (a special CT scan that looks at blood vessels) and/or **DSA** (a detailed imaging test of blood vessels).
  • The aneurysm must be treated by **coiling** (a procedure to block the aneurysm) within 72 hours of the initial bleeding.
  • The patient must give **informed consent**, meaning they agree to participate after understanding the study, before receiving the study medicine.
  • The patient must be an **adult**, which means they are 18 years old or older.
  • Both **male** and **female** patients can participate.

Who cannot join the trial?

4 criteria

  • Patients who are not diagnosed with a subarachnoid hemorrhage. This is a type of bleeding that occurs in the space around the brain.
  • Patients who are not within the specified age range for the study.
  • Patients who belong to a clinical trial group that is not included in this study.
  • Patients who are part of a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

  • Verified

    Amsterdam UMC

    The NetherlandsAmsterdam, The Netherlands

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Nadroparin is a medication used in this clinical trial to help improve outcomes for patients who have experienced a subarachnoid hemorrhage, which is a type of bleeding in the brain. The trial is investigating whether using nadroparin at a therapeutic dose can reduce the 30-day mortality rate compared to using it at a prophylactic dose. Nadroparin is a type of low molecular weight heparin (LMWH) that helps prevent blood clots, which can be a complication after a brain hemorrhage.

What is already known about the treatment

Nadroparin – Nadroparin is administered as an injection, typically under the skin. It is currently being studied in clinical trials for its potential benefits in treating subarachnoid hemorrhage, a type of bleeding in the brain. The main therapeutic indication is to reduce mortality in patients with this condition. At the molecular level, nadroparin works by inhibiting certain factors in the blood clotting process, helping to prevent the formation of harmful clots. It is classified as a low molecular weight heparin, a type of anticoagulant medication.

Investigated diseases

Subarachnoid Hemorrhage – Subarachnoid hemorrhage is a condition where bleeding occurs in the space between the brain and the surrounding membrane, known as the subarachnoid space. This bleeding can lead to a sudden and severe headache, often described as a "thunderclap" headache. As the condition progresses, it may cause symptoms such as neck stiffness, nausea, vomiting, and sensitivity to light. In some cases, individuals may experience confusion, seizures, or loss of consciousness. The bleeding can increase pressure on the brain, potentially leading to further complications. It is crucial to seek immediate medical attention if subarachnoid hemorrhage is suspected.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511679-14-00Estimated enrolment100 patientsSponsorAmsterdam UMC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.